Study shows drug combo belzutifan and cabozantinib could offer new hope for advanced kidney cancer patients.

A recent study by the Dana-Farber Cancer Institute found that a combination of drugs, belzutifan and cabozantinib, showed promising results in treating advanced kidney cancer. For untreated patients, 70% saw a significant response, with some experiencing complete remission. The treatment had manageable side effects. This novel combination could be a new first-line therapy option, offering hope for better outcomes in kidney cancer patients.

2 months ago
3 Articles